miRNA Expression Signatures of Therapy Response in Squamous Cell Carcinomas.

INTRODUCTION

Squamous cell carcinomas (SCC) are a major subgroup of malignant tumors with a platinum-based first-line systematic chemotherapy. miRNAs play a role in various diseases and modulate therapy response as well. The aim of this study was to identify predictive miRNAs in platinum-treated SCCs.

METHODS

miRNA expression data of platinum-treated head and neck (HNSC), cervical (CESC) and lung (LUSC) cancer were collected from the TCGA repositories. Treatment response was defined based on presence or absence of disease progression at 18 months. Responder and nonresponder cohorts were compared using Mann-Whitney and Receiver Operating Characteristic tests. Logistic regression was developed to establish a predictive miRNA signature. Significance was set at FDR < 5%.

RESULTS

The integrated database includes 266 SCC patient samples with platinum-based therapy and available follow-up. We uncovered 16, 103, and 9 miRNAs correlated to chemotherapy response in the CESC, HNSC, and LUSC cohorts, respectively. Eight miRNAs overlapped between the CESC and HNSC subgroups, and three miRNAs overlapped between the LUSC and HNSC subgroups. We established a logistic regression model in HNSC and CESC which included six miRNAs: hsa-miR-5586 (Exp (B): 2.94, = 0.001), hsa-miR-632 (Exp (B): 10.75, = 0.002), hsa-miR-2355 (Exp (B): 0.48, = 0.004), hsa-miR-642a (Exp (B): 2.22, = 0.01), hsa-miR-101-2 (Exp (B): 0.39, = 0.013) and hsa-miR-6728 (Exp (B): 0.21, = 0.016). The model using these miRNAs was able to predict chemotherapy resistance with an AUC of 0.897.

CONCLUSIONS

We performed an analysis of RNA-seq data of squamous cell carcinomas samples and identified significant miRNAs correlated to the response against platinum-based therapy in cervical, head and neck, and lung tumors.